# Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/comparative-effectiveness-of-first-line-palbociclib-plus-letrozole-versus/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Angela DeMichele,Massimo Cristofanilli,Adam Brufsky,Xianchen Liu,Jack Mardekian,Lynn McRoy,Rachel M. Layman,Birol Emir,Mylin A. Torres,Hope S. Rugo,Richard S. Finn |
| Citations | 129 |
| DOI | 10.1186/s13058-021-01409-8 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://breast-cancer-research.biomedcentral.com/counter/pdf/10.1186/s13058-021-01409-8 |
| OpenAlex ID | https://openalex.org/W3137517441 |
| PMID | 33761995 |
| Type | article |
| Year | 2021 |

## Paper authors

- [Jack Mardekian](https://scholariq.org/researchers/jack-mardekian/)

## Paper primary topic

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)

## Paper topics

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer-related Molecular Pathways](https://scholariq.org/topics/cancer-related-molecular-pathways/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.